Physician profile
John MD Eck
NPI 1639186158
$2,410.95
in general payments reported to CMS, 2019-2025
30 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $463 · 2021: $483 · 2022: $325 · 2023: $316 · 2024: $269 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $593.19 | 2021-2025 | Qulipta, Ubrelvy |
| Sanofi-Aventis U.S. LLC | $246.69 | 2019-2024 | |
| Novo Nordisk INC | $184.04 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Mannkind Corporation | $160.78 | 2019-2024 | |
| Abbott Laboratories | $117.89 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.73 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $99.10 | 2021-2024 | Jardiance |
| Amgen INC. | $91.96 | 2019-2020 | |
| Ibsa Pharma INC. | $62.20 | 2020-2021 | |
| Astellas Pharma US INC | $62.19 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $60.75 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $57.89 | 2020-2023 | Seglentis, Livalo |
| Astrazeneca Pharmaceuticals Lp | $52.53 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.59 | 2022-2025 | Cycloset, Xifaxan |
| Kvk-Tech, INC. | $47.99 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $47.52 | 2021-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $42.28 | 2019-2021 | |
| Allergan, INC. | $41.43 | 2019-2020 | |
| Amarin Pharma, INC. | $37.68 | 2020 | |
| Merck Sharp & Dohme LLC | $35.31 | 2019-2020 | |
| Medtronic, INC. | $34.44 | 2023-2025 | Minimed 780g, Minimed 770g |
| Pfizer INC. | $30.00 | 2021 | |
| Bausch Health US, LLC | $29.45 | 2021-2025 | Wellbutrin |
| Neurocrine Biosciences, INC. | $17.68 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.23 | 2023 | Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $16.97 | 2024 | Isturisa, Signifor Lar |
| Takeda Pharmaceuticals U.S.A., INC. | $15.14 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.34 | 2021 | |
| Daiichi Sankyo INC. | $13.50 | 2022 | |
| Sanofi Pasteur INC. | $13.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Eck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.